8 active not recruiting, 6 recruiting, 2 completed, 1 not yet recruiting. 18 Phase 3, 1 Phase 2.
By phase and status
Follow Genmab: new trials by email
Trials (filtered) newest first · largest first
All 18 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer
Rina-S, Bevacizumab - Ovarian Cancer | Phase 3 | Not yet recruiting | 602 | 2026-11-01 | 2026-10-05 |
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | 600 | 2026-10-07 | 2026-10-09 |
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Rina-S, Bevacizumab, Carboplatin - Platinum-Sensitive Ovarian Cancer, Ovarian Cancer | Phase 3 | Recruiting | 688 | 2026-08-28 | 2026-10-07 |
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
Petosemtamab, Cetuximab, FOLFIRI - Left-sided Colorectal Cancer | Phase 3 | Recruiting | 960 | 2026-08-11 | 2026-10-06 |
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer | Phase 3 | Recruiting | 82 | 2026-06-26 | 2026-10-06 |
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Rina-S, Bevacizumab - Ovarian Cancer, Platinum-sensitive Ovarian Cancer | Phase 3 | Recruiting | 544 | 2026-04-03 | 2026-10-06 |
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Rina-S, IC - Endometrial Cancer, Recurrent or Progressive Endometrial Cancer | Phase 3 | Recruiting | 660 | 2025-11-28 | 2026-10-06 |
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer | Phase 3 | Active not recruiting | 584 | 2025-02-07 | 2026-09-28 |
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Acasunlimab, Pembrolizumab, Docetaxel - PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Phase 3 | Active not recruiting | 191 | 2024-11-25 | 2026-10-06 |
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Epcoritamab, Rituximab, Lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | 379 | 2024-08-13 | 2026-04-08 |
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Epcoritamab, Prednisone, Rituximab - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | 1095 | 2024-02-05 | 2026-08-04 |
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Epcoritamab, Cyclophosphamide, Rituximab - Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | 900 | 2023-02-08 | 2026-09-11 |
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Epcoritamab, Investigator's Choice Chemotherapy - Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | 72 | 2022-10-08 | 2026-05-05 |
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Epcoritamab, Rituximab, Lenalidomide - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | 549 | 2022-09-20 | 2026-07-08 |
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
tisotumab vedotin, topotecan, vinorelbine - Cervical Cancer | Phase 3 | Completed | 502 | 2021-02-22 | 2026-02-24 |
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Epcoritamab, Investigator's Choice Chemotherapy - Diffuse Large B-cell Lymphoma | Phase 3 | Active not recruiting | 483 | 2021-01-13 | 2026-05-22 |
Zalutumumab in Patients With Non-curable Head and Neck Cancer
Zalutumumab, Control - Head and Neck Cancer, Squamous Cell Cancer | Phase 3 | Completed | 286 | 2006-11-01 | 2013-10-15 |
Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker
HuMax-CD4, Placebo, Humax-CD4 - Rheumatoid Arthritis | Phase 2 / Phase 3 | Terminated | 83 | 2002-03-04 | 2023-04-28 |
Conditions studied
Ovarian Neoplasms (5) · Lymphoma, Large B-Cell, Diffuse (4) · Fallopian Tube Neoplasms (3) · Lymphoma, Non-Hodgkin (3) · Neoplasms (3) · Lymphoma (2) · Lymphoma, Follicular (2) · Recurrence (2) · Arthritis, Rheumatoid (1) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Neoplasms, Squamous Cell (1)
Interventions
Gemcitabine (5) · Bevacizumab (4) · Rituximab (4) · Lenalidomide (3) · Paclitaxel (3) · Topotecan (3) · Cetuximab (2) · Cyclophosphamide (2) · Doxorubicin (2) · Irinotecan (2) · Oxaliplatin (2) · Prednisone (2) · Vincristine (2) · liposomal doxorubicin (2) · 1-dodecylpyridoxal (1)
Countries
United States (14) · Belgium (11) · Canada (11) · France (11) · Japan (11) · Poland (11) · Spain (9) · Australia (8) · Brazil (8) · China (8) · Hungary (8) · Italy (8) · Netherlands (8) · Puerto Rico (8) · United Kingdom (8)
Results publications
PMID 21377930, PMID 38959480, PMID 41371238, PMID 41644383, PMID 42680635
NIH funding
2023 (5), 2025 (2)